Cite
HARVARD Citation
Gligorov, J. et al. (2017). Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients. European journal of cancer. pp. 237-246. [Online].